Antibody-drug conjugates (ADCs) are a series of targeted therapeutic agents used in cancer treatment. They combine the precise targeting characteristics of monoclonal antibodies with cytotoxic payloads to achieve precise attacks on diseased areas, without causing adverse effects on healthy cells and tissues. Genetech Pharmaceuticals closely follows this trend, leveraging its efficient R&D platform to address the scarcity of Eribulin and other anti-toxin antibody selections for domestic users, facilitating pharmacokinetic (PK) analysis of ADC drugs, and accelerating the development process of ADC medications.
